Fair Trade Commission Approves CG Inbites-Inbites Ecosystem Merger
CG Inbites announced on the 29th that it received approval for the corporate merger involving the incorporation into the Inbites ecosystem from the Fair Trade Commission on the 28th.
The Fair Trade Commission completed its approval after reviewing whether the horizontal and vertical integration with the clinical trial outsourcing (CRO) business of Inbites BioCore, which is already part of the Inbites ecosystem, would restrict competition. This is because CG Inbites and its affiliates operate businesses related to pharmaceutical research and development, manufacturing, and CRO services.
As a result, the Inbites ecosystem has established a full-cycle value chain consisting of 10 bio and healthcare companies, including Inbites BioCore, HealthConnect, Inbites Genomics, ProCagen, and Inbites Ventures. With this merger approval, the legal procedures have also been completed.
After joining the Inbites ecosystem in June, CG Inbites changed its company name from the former Crystal Genomics to CG Inbites.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, the Inbites ecosystem is pursuing its business with the goal of implementing personalized health management and precision medical services based on data and technology.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.